Aspira Women's Health Inc. 8-K

What Happened
Aspira Women's Health Inc. announced on May 26, 2026 (filing dated May 26, 2026) that it entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation, effective May 20, 2026. The agreement establishes a framework for joint biomedical research and development projects between Aspira and the Cleveland Clinic.

Key Details

• Partnering Fee: $125,000 total, payable as $50,000 within 30 days of the May 20, 2026 effective date and $25,000 on each of the first, second, and third anniversaries. The fee is non‑refundable and not creditable against other payments.
• Term: Initial term of five years from May 20, 2026, extendable by mutual agreement.
• Termination: Either party may terminate on 60 days’ notice, for uncured material breach (30‑day cure period), or immediately if the arrangement jeopardizes Cleveland Clinic’s tax‑exempt status.
• Other provisions: Agreement includes customary confidentiality, HIPAA and healthcare‑compliance obligations, insurance, indemnification, and is non‑exclusive.

Why It Matters
This agreement creates a formal, multi‑year collaboration channel with a leading research and clinical institution, which may enable joint R&D work and future statements of work that could include reimbursed costs, milestones or royalties. The near‑term financial commitment by Aspira is modest and spread over four years ($125,000 total, non‑refundable); the deal itself does not disclose specific development milestones, revenues, or guaranteed future payments. Investors should view this as a strategic R&D partnership that formalizes cooperation with Cleveland Clinic while exposing Aspira to limited immediate cash obligations.